Uncategorized
US FDA staff questions dosing of Lucentis eye drug
WASHINGTON (Reuters) - U.S. drug reviewers on Tuesday said Roche Holding AG's eye drug Lucentis
(ranibizumab injection) appeared to help patients with diabetic macular edema (DME), but questioned whether two
different doses of the drug were equally safe and effective.